Monteleone Palmiero, Fabrazzo Michele, Tortorella Alfonso, La Pia Silvestro, Maj Mario
Institute of Psychiatry, University of Naples SUN, Naples, Italy.
J Clin Psychopharmacol. 2002 Aug;22(4):424-6. doi: 10.1097/00004714-200208000-00015.
Weight gain is a widely reported side effect of clozapine, but no predictive factor has been identified so far. We investigated whether pretreatment values of circulating leptin or its early changes during clozapine administration could predict the long-term weight gain induced by the drug. Body weight and plasma levels of leptin were prospectively measured in 22 patients (13 men and 9 women) with drug-resistant schizophrenia undergoing a long-term treatment with clozapine. At the end of the second week of clozapine administration, circulating leptin increased much more than weight gain, and this increase was inversely correlated to body weight increase observed after 6 and 8 months of treatment. These findings suggest that early changes in leptin secretion may predict long-term weight gain in the course of clozapine administration.
体重增加是氯氮平一种广泛报道的副作用,但目前尚未发现预测因素。我们研究了循环瘦素的预处理值或其在氯氮平给药期间的早期变化是否能预测该药物引起的长期体重增加。对22例(13例男性和9例女性)耐药性精神分裂症患者进行了前瞻性测量,这些患者正在接受氯氮平长期治疗,测量了他们的体重和血浆瘦素水平。在氯氮平给药第二周结束时,循环瘦素的增加远超过体重增加,且这种增加与治疗6个月和8个月后观察到的体重增加呈负相关。这些发现表明,瘦素分泌的早期变化可能预测氯氮平给药过程中的长期体重增加。